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Abstract
Targeted therapy based on adjustment of microRNA (miRNA)s activity takes great promise
due to the ability of these small RNAs to modulate cellular behavior. However, the efficacy
of miR-101 replacement therapy to hepatocellular carcinoma (HCC) remains unclear. In
the current study, we first observed that plasma levels of miR-101 were significantly lower
in distant metastatic HCC patients than in HCCs without distant metastasis, and down-
regulation of plasma miR-101 predicted a worse disease-free survival (DFS, P<0.05). In
an animal model of HCC, we demonstrated that systemic delivery of lentivirus-mediated
miR-101 abrogated HCC growth in the liver, intrahepatic metastasis and distant metastasis
to the lung and to the mediastinum, resulting in a dramatic suppression of HCC develop-
ment and metastasis in mice without toxicity and extending life expectancy. Furthermore,
enforced overexpression of miR-101 in HCC cells not only decreased EZH2, COX2 and
STMN1, but also directly down-regulated a novel target ROCK2, inhibited Rho/Rac
GTPase activation, and blocked HCC cells epithelial-mesenchymal transition (EMT) and
angiogenesis, inducing a strong abrogation of HCC tumorigenesis and aggressiveness
both in vitro and in vivo. These results provide proof-of-concept support for systemic deliv-
ery of lentivirus-mediated miR-101 as a powerful anti-HCC therapeutic modality by repress-
ing multiple molecular targets.
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Author Summary
Human hepatocellular carcinoma (HCC) is one of the most common malignancy world-
wide and among the leading causes of cancer-related death. HCC is often diagnosed at an
advanced stage and there is still no effective therapeutic strategy for non-resectable HCCs.
It has been suggested that the therapeutic delivery of certain miRNA(s) has a unique ad-
vantage in clinical use. We first find that the plasma levels of miR-101 are significantly
down-regulated in HCC patients with distant metastasis and associated closely with HCCs
progression and/or worse disease-free survival (DFS). Next, we identify that systemic de-
livery of lentivirus-mediated miR-101 in an orthotopic liver implanted HCC model of
mouse, not only suppresses tumor xenograft growth in the liver, but also substantially
blocks intrahepatic metastasis and distant metastasis to the lung and to the mediastinum,
resulting in a dramatic abrogation of HCC tumorigenesis and progression in mice without
toxicity. Furthermore, functional and/or mechanistic studies of miR-101 demonstrate that
miR-101 in HCC cells inhibits Rho/Rac GTPase activation, and blocks HCC cells epitheli-
al-mesenchymal transition (EMT) and angiogenesis, inducing a strong abrogation of HCC
tumorigenesis and aggressiveness both in vitro and in vivo.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancy worldwide [1]. In
China, HCC is the second highest cancer killer, which along accounts for 53% of all liver cancer
deaths in the world [2]. HCC is often diagnosed at an advanced stage and there is no effective
therapeutic strategy for non-resectable HCCs. so far, since highly active drug-metabolizing
pathways and multidrug resistance transporter proteins in tumor cells always diminish the effi-
cacy of current therapeutic regimens for HCC. Therefore, alternative modalities of treatment
are urgently needed for this uniformly fatal disease.
MicroRNA (miRNA)s are a class of highly conserved short RNAs that suppress gene expres-
sion [3] and have a functional contribution to cellular transformation and/or tumorigenesis
[4,5]. In human neoplasms, some miRNAs are often up-regulated and may perform an onco-
genic function, while most miRNAs are down-regulated and have a tumor suppressive activity
[6]. Thus, potential therapeutic approaches in diseases, such as cancer, that target specific
miRNAs have recently attracted attention [7]. Inhibition of oncogenic miRNAs through the
use of antisense reagents is clearly one of the approaches [8]. On the other hand, miRNA-
replacement therapy is another efficacious strategy [9]. In HCC, it was reported that systemic
administration of miRNA (miR)-26a in a transgenic mouse HCC model could result in a dra-
matic suppression of HCC cell proliferation, induction of tumor-specific apoptosis and protec-
tion from disease progression without toxicity [10].
Recently, we and other groups have found that the levels of a specific miRNA, miR-101,
were frequently down-regulated in human HCC tissues, and ectopic overexpression of miR-
101 dramatically inhibited HCC cells tumorigenicity and invasiveness in vitro by targeting
MCL-1 and FOS, respectively [11,12]. More recently, it has been reported that miR-101 could
inhibit autophagy and enhance cisplatin-induced apoptosis in HCC cells by targeting STMN1
[13]. In other solid tumors, the levels of miR-101 were also decreased in neoplastic tissues
[14–17], and miR-101 could inhibit the tumorigenesis and/or cancer progression by repressing
the oncogenes EZH2 and COX2 [17–20]. These data suggest a powerful anti-tumorigenic activ-
ity of miR-101 in different human cancers. To date, however, the in vivo efficacy of miR-101 re-
placement therapy to human cancers, such as HCC, has not been elucidated. In the current
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study, we thus determined to investigate the therapeutic efficacy of systemic delivery of
lentivirus-mediated miR-101 in an orthotopic liver implanted HCCmodel of mouse, and the
tumor repressive functions of miR-101 in HCC and underling mechanisms were further
studied.
Results
Down-regulation of plasma MiR-101 is a frequent event in HCC patients
with distant metastasis and predicts worse prognosis
The plasma levels of miR-101 were examined by Real-time PCR in 163 HCC patients and 50
healthy donors. To identify a single, optimal cutpoint for mature miR-101, ROC curve analysis
was applied to our HCC cohort to determine the cutoff score for high or low expression of
miR-101 [21]. Tumors designated as “high expression” for miR-101 were those with scores
above the value of 2.243928. The average plasma levels of miR-101 were significantly lower in
HCC patients with distant metastasis than that in HCCs without distant metastasis and control
healthy donors (Fig. 1A). High expression of plasma miR-101 was examined in 88/163 (54.0%)
of HCC patients. Correlation analysis showed that low level of plasma miR-101 in HCC pa-
tients was significantly associated with a more aggressive phenotype (Table 1, p<0.05). Further
survival analysis established that the plasma level of miR-101 is an independent prognostic
factor for HCC patient survival (p<0.0001, Fig. 1B, Table 2).
It has been reported that HBx-mediated miR-101 down-regulation and subsequent induc-
tion of aberrant DNMT3A expression contributes to HBV mediated hepatocarcinogenesis
[22]. We thus examined the levels of miR-101 in HBV-negative and HBV-positive HCC pa-
tient’s plasma. We found that there are no significant differences between the plasma levels of
miR-101 in HBV-negative and HBV-positive HCC patients (S1A Fig.). At the same time, so
are the results in HBV-negative and HBV-positive HCC patient’s plasma with distant metasta-
sis (S1B Fig.). Consequently, it is unlikely that HBV infection itself induced the differential ex-
pression patterns of plasma miR-101 in our set of HCCs.
Therapeutic delivery of miR-101 suppresses tumor growth,
angiogenesis and metastasis in an orthotopic liver implanted HCC
model of mouse
In our study, we subsequently assessed the therapeutic efficacy of miR-101 via tail vein
delivery to an orthotopic liver implanted HCC model of mouse. Lent-miR-101, control lent-
miR-ctr and physiological saline (NaCl) was administered, respectively, to mice by tail vein at
one week after the preparation of the mouse HCC model, 2 times a week for a month. When
mice got moribund, mice were euthanized. The liver, the lung and tumor xenograft were
assessed.
Firstly, we observed that the levels of coGFP in the liver, the lung and tumor tissues of lent-
miR-101 treated mice were equivalent to that in lent-miR-ctr treated mice, exhibiting over 90%
infection efficiency (Fig. 2A, upper panel). But the expression levels of miR-101 in the liver, the
lung and tumor tissues were significantly higher in lent-miR-101 treated mice than that in both
control mice (p<0.0001, Fig. 2A, down panel). Meanwhile, the administrations of lent-miR-
101 and lent-miR-ctr did not cause acute liver toxicity, as demonstrated by the maintenance of
normal levels of serum markers of liver function (S1 Table) and an absence of overt histological
evidence of toxicity (S2 Fig.).
Next, we found that mice in control groups developed larger sized primary tumors than that
in lent-miR-101 treated mice (Fig. 2B, p<0.01). Moreover, we assessed the microvessel density
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(MVD) of tumors by Immunohistochemistry (IHC) staining of CD34[23] . The MVD-CD34
of tumors in lent-miR-101 group (mean, 18; range, 9–46) was significantly smaller than that in
both lent-miR-ctr (mean, 41; range, 25–69) and NaCl (mean, 43; range, 22–78) treated groups
(p<0.01, Fig. 2C). Furthermore, we examined that the number of intrahepatic and pulmonary
metastatic nodules was dramatically decreased in lent-miR-101 treated group compared to that
in both control groups (p<0.01, Fig. 2D and 2E), and the mean survival time in lent-miR-101-
treated mice was significantly longer than that in the control mice (p<0.05, Fig. 2F).
MiR-101 directly targets ROCK2 3’UTR
In our study, the putative targets of miR-101 were predicted using target prediction programs,
miRanda and TargetScan. We evaluated that besides the target genes of EZH2, COX2, STMN1,
MCL-1 and FOS identified previously [11–13,17,18], the 3’-UTR of ROCK2mRNA contains a
complementary site for the seed region of miR-101, the ROCK2 gene was an additional poten-
tial target of miR-101 (Fig. 3A).
Figure 1. Analysis of miR-101 levels in human plasma samples by real-time PCR and Kaplan-Meier
analysis for HCC patients DFS according to the plasma levels of miR-101. A. Expression levels of miR-
101 in human plasma samples from healthy donors (n = 50) and HCC patients with distant metastasis (n =
16) and without distant metastasis (n = 147).B. Kaplan-Meier analysis for HCC patients DFS according to
plasma levels of miR-101. The levels of miR-101 was analyzed by real-time PCR, and ROC curve analysis
was applied to determine the cutoff score for high expression (n = 88) and low expression of plasmamiR-101
(n = 75).
doi:10.1371/journal.pgen.1004873.g001
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To verify whether or not ROCK2 is a direct target of miR-101, ROCK2 3’-UTR (Fig. 3A) and
two mutants containing the miR-101 binding sites were cloned downstream of the luciferase
open reading frame. These reporter constructs were used to cotransfect HCC LM9 cells. The
luciferase activity assays showed that increased expression of miR-101 upon infection signifi-
cantly affected the luciferase expressions of ROCK2 in LM9 cells. Conversely, when we per-
formed luciferase assays using a plasmid harboring the 3’-UTR of ROCK2mRNA, in which
the binding sites for miR-101 were inactivated by site-directed mutant genesis, the luciferase
activities of mutant reporters were unaffected by the simultaneous infection of miR-101
(Fig. 3B).
Table 1. Correlation of plasma miR-101 expression with patients’ clinicopathologic variables in human hepatocellular carcinomas.
miR-101Variable
All cases Low expression High expression P value*
Age (years) 0.231
 48.2† 80 33 (41.3%) 47 (58.8%)
> 48.2 83 42 (50.6%) 41 (49.4%)
Sex 0.306
Male 136 65 (47.8%) 71 (52.2%)
Female 27 10 (37.0%) 17 (63.0%)
Etiology 0.581
HBV 134 63 (47.0%) 71 (53.0%)
None 29 12 (41.4%) 17 (58.6%)
AFP (ng/ml) 0.405
20 84 36 (42.9%) 48 (57.1%)
>20 79 39 (49.4%) 40 (50.6%)
Liver cirrhosis 0.272
Yes 108 53 (49.1%) 55 (50.9%)
No 55 22 (40.0%) 33 (60.0%)
Tumor size (cm) 0.001
5 85 29 (34.1%) 56 (65.9%)
>5 78 46 (59.0%) 32 (41.0%)
Tumor multiplicity 0.000
Single 111 40 (36.0%) 71 (64.0%)
Multiple 52 35 (67.3%) 17 (32.7%)
Differentiation 0.172
Well 22 7 (31.8%) 15 (68.2%)
Moderate 93 48 (51.6%) 45 (48.4%)
Poor 40 15 (37.5%) 25 (62.5%)
Undifferentiated 8 5 (62.5%) 3 (37.5%)
Stage 0.000
I 20 3 (15.0%) 17 (85.0%)
II 61 15 (24.6%) 46 (75.4%)
III 53 30 (56.6%) 23 (43.4%)
IV 29 27 (93.1%) 2 (6.9%)
Distant metastasis
M1 16 16 (100%) 0 (0%)
MX 147 61 (40.8%) 86 (59.2%)
*Chi-square test
†Mean age
HBV indicates hepatitis B virus
AFP indicates alpha-fetoprotein.
doi:10.1371/journal.pgen.1004873.t001
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In addition, the mRNA and protein levels of ROCK2 were all substantially reduced after
miR-101 overexpression in LM9 and Huh7 cells (Fig. 3C and 3D). On the other hand, knock-
ing down miR-101 in HepG2 and miR-101-LM9 cells, dramatically increased protein levels of
ROCK2 (Fig. 3E). Furthermore, IHC staining showed that ROCK2 expressions were down-
regulated in HCC tissues of mice treated with systemic delivery of lent-miR-101 (Fig. 3F). At
the same time, we also confirmed that STMN1 and COX2 are the other targets of miR-101 in
HCC (S3–S4 Fig.).
Table 2. Univariate and multivariate analysis of different prognostic factors in 163 patients with hepatocellular carcinoma.
Univariate analysis* Multivariate analysis†Variable
All cases Mean survival (months) P value HR (95% CI) P value
Age (years) 0.491
 48.2‡ 80 39.4
> 48.2 83 37.0
Sex 0.349
Male 136 37.9
Female 27 39.1
Etiology 0.767
HBV 134 33.5
None 29 38.7
AFP (ng/ml) 0.000 2.111 (1.219–3.654) 0.008
20 84 47.3
>20 79 28.6
Liver cirrhosis 0.766
Yes 108 37.7
No 55 39.1
Tumor size (cm) 0.001 1.348 (0.784–2.318) 0.281
5 85 45.9
>5 78 31.3
Tumor multiplicity 0.000 1.462 (0.827–2.584) 0.191
Single 111 45.7
Multiple 52 24.3
Differentiation 0.273
Well/moderate 115 39.8
Poor/undifferentiated 48 34.7
Stage 0.000 2.733 (1.375–5.434) 0.004
I/II 81 50.2
III/ IV 82 27.0
Distant metastasis 0.000 1.541 (0.811–2.929) 0.187
MX 147 41.0
M1 16 18.2
miR-101 expression 0.000 0.480 (0.270–0.852) 0.012
Low expression 75 25.2
High expression 88 51.5
*Log-rank test
†Cox regression model
‡mean age
HR indicates hazards ratio
CI indicates confidence interval
HBV indicates hepatitis B virus
AFP indicates alpha-fetoprotein.
doi:10.1371/journal.pgen.1004873.t002
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Figure 2. Systemic delivery of lent-miR-101 suppresses tumor growth, angiogenesis andmetastasis in the orthotopic liver implanted HCCmodel
of mouse. A. Upper panel, laser confocal microscopy showed efficient infection of lentivirus to the liver, the lung and tumor xenografts of mice, as indicated
by coGFP expression. Down panel, the levels of miR-101 in the liver, the lung and tumor tissues were significantly higher in lent-miR-101 treated mice than
that in both control mice (P<0.001). Data is presented as mean SE. B. Representative tumor xenografts in the liver of mice in different (NaCl, lent-miR-ctr
and lent-miR-101) treated groups. P, primary tumor; M, metastatic nodule. The average size of primary tumors in the liver was 10.753.25 mm in diameter in
NaCl treated group (n = 8), 11.513.71 mm in lent-miR-ctr treated group (n = 8), and 2.781.25 mm in lent-miR-101 treated group (n = 7). C. Representative
images of microvessel density (MVD) of implanted primary tumor examined by IHC staining of CD34 in lent-miR-101 treated and 2 control groups.D.
Systemic Delivery of mir-101 Inhibits HCC
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Ectopic expression of miR-101 inhibits HCC cell motility, invasion and
epithelial-mesenchymal transition (EMT) in vitro
The Matrigel invasion and Wound healing assays demonstrated that miR-101 overexpression
substantially decreased both LM9 and Huh7 HCC cells motility and invasive capability
(Fig. 4A; S5–S6A Fig.). Moreover, after miR-101 overexpression in LM9 and Huh7 lines, the
expression levels of all tested epithelial markers (E-cadherin, a-catenin and b-catenin)
increased, while the levels of mesenchymal markers (fibronectin, N-cadherin and vimentin)
decreased (Fig. 4B and 4C; S6B–S6C Fig.).
Overexpression of miR-101 in HCC cells suppresses metastasis in vivo
We further evaluated the in vivo effects of miR-101 overexpression on HCC cell metastasis
using an experimental in vivometastasis assay. As demonstrated in Fig. 4D and 4E, the num-
bers of micrometastatic lesions in the liver and the lungs of mice were markedly reduced in
lent-miR-101-LM9 group, as compared to that in the control groups.
MiR-101 inhibits RhoA/Rac1 GTPase in HCC cells
It is known, during tumor invasion and metastasis, changes in Rho-GTPase activity often lead
to subsequent reorganization of actin cytoskeleton[4,24]. We investigated if miR-101 modifies
HCC cell cytoskeleton rearrangement and inhibits Rho-GTPase. The F-actin staining showed
that the stress fiber was observed in the control lent-miR-ctr-LM9 and lent-miR-ctr-Huh7
cells, but not in lent-miR-101-LM9 and lent-miR-101-Huh7 cells (Fig. 5A and S7A Fig.) and
meanwhile, a lower level of GTP-RhoA, GTP-Rac1 and GTP-cdc42 was examined in lent-miR-
101-LM9 and lent-miR-101-Huh7 cells as compared to that in lent-miR-ctr-LM9 and lent-
miR-ctr-Huh7 cells (Fig. 5B and S7B Fig.).
Overexpression of miR-101 in HCC cells inhibits angiogenesis in a
chicken chorioallantoic membrane (CAM) model
To test the function of miR-101 in regulating angiogenesis, we also examined the effect of lent-
miR-101-LM9 and lent-miR-101-Huh7 cells on angiogenesis in a CAMmodel. The results
showed that ectopic overexpression of miR-101 in LM9 and Huh7 cells dramatically sup-
pressed the angiogenesis in vivo (Mock versus lent-miR-ctr, and versus lent-miR-101 LM9
cells were 112%12.1% versus 98.67%8.84%, and versus 46.33%9.67%, and mock versus
lent-miR-ctr, and versus lent-miR-101 Huh7 cells were 115%8.6% versus 100%10.8%, and
versus 48%6.3%, Fig. 5C).
Discussion
It is known that most tumors are characterized by globally decreased expression of miRNAs[6]
and enforced down-regulation of certain specific miRNAs may enhance cellular transforma-
tion and tumorigenesis[25]. Recently, accumulative evidences suggested that therapeutic deliv-
ery of certain miRNA(s) has a unique advantage in clinical use, since an individual miRNA
may influence the cellular behavior through the regulation of multiple target genes and net-
works[26]. We and other groups previously identified a frequently down-regulated miRNA,
Representative images of metastatic nodules in the liver, in the lung and in the mediastinum of mice in different treatment groups (indicated by arrows). E.
The mean number of metastasis in lenti-miR-101 treated group (liver: 9.42.9; lung: 11.32.5, n = 7) was significantly larger than that in control NaCl (liver:
32.15.1; lung: 39.46.0, n = 8) and lent-miR-ctr (liver: 30.85.4; lung: 40.95.4, n = 8) treated groups (P<0.01). Data is presented as mean SE. F. The
difference in survival time of mice between the lenti-miR-101 group and 2 control (NaCl and lent-miR-ctr) groups was statistically significant (P<0.05).
doi:10.1371/journal.pgen.1004873.g002
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Figure 3. ROCK2 is the target of miR-101. A. Schematic of predicted miR-101-binding sites in the 30UTR of ROCK2. B.MiR report constructs containing a
wild-type and 2 mutated ROCK2 3’UTR were transfected into LM9 cells, respectively. Relative repression of firefly luciferase expression was standardized to
a transfection control. The reporter assays were performed 3 times with essentially identical results. C. Left, the levels of miR-101 by Real-time PCR in the
lenti-miR-101 and control MOCK and lent-miR-ctr treated LM9 cells. Right, real-time PCR examination of mRNA levels of ROCK2 between the lenti-miR-101
and control lent-miR-ctr treated LM9 cells. LM9 cells were infected with lent-miR-ctr or lent-miR-101 for 72 hours. Down, ectopic overexpression of miR-101
by lenti-miR-101 reduces the levels of ROCK2 proteins in LM9 cells, as compared to that in both MOCK and lent-miR-ctr treated LM9 cells.D. Left, the levels
of miR-101 by Real-time PCR in the lenti-miR-101 and mock and lent-miR-ctr treated Huh7 cells. Right, real-time PCR examination of mRNA level of ROCK2
between the lenti-miR-101 and control lent-miR-ctr treated Huh7 cells. Huh7 cells were infected with lent-miR-ctr or lent-miR-101 for 72 hours. Down, ectopic
overexpression of miR-101 by lenti-miR-101 reduces the levels of ROCK2 proteins in Huh7 cells, as compared to that in both Mock and lent-miR-ctr treated
Huh7 cells. E. Upper, protein expression of ROCK2 is up-regulated in HCC HepG2 cells after the down-regulation of miR-101 by anti-miR-101, as compared
to that in control Mock and anti-miR-NC HepG2 cells. Down, protein expressions of ROCK2 is up-regulated in lent-miR-101-LM9 cells after the down-
regulation of miR-101 by anti-miR-101, as compared to that in control anti-miR-NC cells. F. IHC staining showing down-regulated expressions of ROCK2 in
HCC tissues of mice treated with systemic delivery of lent-miR-101, as compared to that treated with NaCl or lent-miR-ctr.
doi:10.1371/journal.pgen.1004873.g003
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Figure 4. Enforced overexpression of miR-101 inhibits HCC LM9 cells invasion and EMT in vitro and reducesmetastasis in vivo. A. The invasive
properties of HCC LM9 cells transfected with lent-miR-ctr, lent-miR-101, si-STMN1, and si-ROCK2 were analyzed by an invasion assay using a Matrigel
Invasion Chamber. Migrated cells were plotted as the average number of cells per field of view from 3 independent experiments (**, P<0.01).B. Expression
levels of the epithelial markers E-cadherin, α-catenin and β-catenin and the mesenchymal markers fibronectin, N-cadherin and vimentin were analyzed by
Western blot between lent-miR-101 and control lent-miR-ctr LM9 cells.C. IF staining (red signal) showing that the Epithelial markers E-cadherin, α-catenin,
β-catenin were up-regulated and mesenchymal markers fibronectin, N-cadherin and vimentin were down-regulated in lent-miR-101 treated LM9 cells, as
compare to that in lent-miR-ctr cells.D. The in vivo effects of miR-101 on HCC cell metastasis using an experimental metastasis assay, in which lent-miR-
101, control lent-miR-ctr and mock LM9 cells were injected into the tail vein of SCID mice, respectively. Metastatic tumor growth in the liver and in the lung
was assessed. Representative metastatic nodules and H&E staining of metastatic tumors in the liver and in the lung are indicated by arrows. E. The number
of metastatic nodules in the liver and in the lungs of mice (n = 8 per group) 8 weeks after tail vein injection of let-miR-101 LM9 cells (meanSE, liver: 2.80.8,
lung: 9.84.7), mock LM9 cells (meanSE, liver: 9.81.0, lung: 33.54.6) and lent-miR-ctr LM9 cells (meanSE, liver: 9.5 1.6, lung: 33.5 6.7).
doi:10.1371/journal.pgen.1004873.g004
Systemic Delivery of mir-101 Inhibits HCC
PLOSGenetics | DOI:10.1371/journal.pgen.1004873 February 18, 2015 10 / 21
Figure 5. Ectopic overexpression of miR-101 inhibits stress fiber formation in vitro and angiogenesis
in a CAMmodel, and a proposed regulatory loop of miR-101 in HCC tumorigenesis andmetastasis. A.
Staining for F-actin demonstrated that the stress fiber formation in lent-miR-101 treated LM9 cells decreased
when compared with that in lent-miR-ctr LM9 cells.B. Total and active forms of Rho-GTPases, including
RhoA, Rac1, and cdc42 were compared between lent-miR-ctr and lent-miR-101 treated LM9 cells by
Western blot analysis. GTP-bound (active) forms of RhoA, Rac1, and cdc42 were pulled down and examined
byWestern blot using corresponding antibodies. Active forms of RhoA, Rac1 and Cdc42 were lower in lent-
miR-101 LM9 than that in lent-miR-ctr LM9 cells.C. Lent-miR-101 LM9 and Huh7 cells inhibits angiogenesis
in a CAMmodel. Left panel, representative plugs from different (Mock, lent-miR-ctr and lent-miR-101 LM9
and Huh7 cells) treated groups. Right panel, the number of blood vessels was counted from 6 replicate
experiments, and normalized to that of the lent-miR-ctr group as relative angiogenesis. The data were
meanSD. ** indicates the significant change with P<0.01.D. A proposed model in which miR-101 inhibits
tumorigenesis and metastasis of HCC by repression of multiple target genes and tumor activators.
doi:10.1371/journal.pgen.1004873.g005
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miR-101, in various solid tumors including HCC [11,12]. In the present study, our initial
Quantitative PCR demonstrated that in a large cohort of HCC patients, all HCCs with distant
metastasis had a low level of plasma miR-101, and it was associated closely with an advanced
clinical stage and predicted poor prognosis. Next, in an orthotopic liver implanted HCC
model of mouse, we clearly showed that systemic delivery of lenti-miR-101 not only induced a
dramatic suppression of tumor growth in the liver, but also substantially diminished HCC
intrahepatic metastasis and distant metastasis to the lung and to the mediastinum, resulting in
a dramatic suppression of HCC in mice without a measurable toxicity. The results reveal that
therapeutic delivery of lenti-miR-101 in mouse potently inhibits HCC development/metastasis
in vivo and thereby, establishing a principle that miR-101 may be useful as an effective anti-
HCC agent through its ability to broadly suppress HCC cells tumorigenicity and invasiveness.
In this study, we chose a lentivirus-based vector system as miR-101 delivery vehicle, since
it is an attractive platform for regulatory gene delivery [27,28]. Importantly, the safety of
using the lentiviral vector in preclinical research and clinical trials is a minimal concern and
providing a therapeutic benefit for the patients [29–31]. In our mouse HCC model of the pres-
ent study, we did observe that systemic delivery of lent-miR-101 exhibited an over 90% infec-
tive efficiency and high expression levels of miR-101 in the liver, the lung and tumor tissues of
mice without toxicity, indicating that lentivirus provides an effective and nontoxic means to
deliver miRNAs to mouse. Overall, our data hereby provide a basis for the concept that the sys-
temic administration of miR-101 mediated by lentivirus might be a clinically viable anti-HCC
therapeutic strategy. These results prompt us to further explore the functions and excise molec-
ular mechanisms of miR-101 in the development and/or progression of HCC.
Firstly, we observed that systemic delivery of lent-miR-101 in the mouse HCC model sub-
stantially inhibited tumor angiogenesis. In a CAMModel, we also demonstrated that enforced
expression of miR-101 in HCC cells could diminish angiogenesis. In addition, ectopic overex-
pression of miR-101 in HCC cells not only suppressed cell motility, invasion and EMT, but
also blocked the formation of cells stress fiber. In an experimental in vivometastasis model of
SCID mouse, we further showed that the tail-vein-injection of miR-101-overexpressing HCC
cells led to a significant decrease in the number of metastatic lesions in the liver and in the
lung. These data, collectively, strongly supported that miR-101 plays a crucial tumor suppres-
sive role in the control of HCC aggressive process.
We know that miRNAs exert their functions through regulating downstream target gene(s).
The oncogenes, EZH2 and COX2, were two targets of miR-101 first identified in 2008 [17,18]
and they were confirmed in our HCC cells of the present study (S4 Fig. and S8 Fig.). EZH2 con-
tributes to cancer metastasis via regulation of actin-dependent cell adhesion and migration
[32] and implicated in EMT [33] and angiogenesis induction [34]. In human HCCs, we previ-
ously reported that both EZH2 and COX2 are frequently overexpressed in HCCs and positively
correlated with high aggressive and/or poor prognostic phenotypes [21,35]. In addition,
COX-2 inhibitors could prevent HCC cell growth both in vitro and in vivo [35,36]. These data
suggest that EZH2 and COX2 are two important targets of miR-101 to suppress HCC. In 2009,
another direct target gene of miR-101,MCL-1, was identified by our group and enforced ex-
pression of miR-101 in HCC cells could dramatically decreaseMCL-1 levels and thus, promot-
ing apoptosis to suppress tumorigenicity [11]. Almost at the same time, Li et al [12] showed
that miR-101 significantly repressed the abilities of HCC cell migration and invasion by target-
ing the FOS oncogene. And FOS can induce EMT in mammary epithelial cells [37]. More re-
cently, Xu and colleagues [13] reported that miR-101 could inhibit autophagy and enhance
cisplatin-induced apoptosis in HCC cells by targeting STMN1. STMN1 is a key microtubule-
regulatory protein and associated positively with HCCs vascular invasion, intrahepatic metas-
tasis and advanced clinical stage [38,39]. In a series of in vitro and in vivo experiments of our
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present study, we not only confirmed that STMN1 is a target of miR-101 (S2 Fig.), but also
identified a novel direct target of miR-101, ROCK2, in HCC. Overexpression of ROCK2 was
frequently examined in HCCs and it could induce EMT [4] and a more aggressive biological
behavior [40]. These data suggest that miR-101 could enhance its inhibiting effects on HCC by
targeting an additional oncogene ROCK2.
Cytoskeletal reorganization exemplified by the formation of stress fiber bundling arrays is
essential for the contractile motion of cancer cells [24]. In addition, the RhoA/ROCK signaling
plays important roles in multiple aspects of VEGF-mediated angiogenesis [41]. Among the
members of the Rho family, RhoA, Rac1 and Cdc42 are 3 representative members defined in
modulating the actin cytoskeleton [42] and may lead to EMT [43], and RhoA activation may
induce the formation of stress fibers [44]. In our study, we found that after miR-101 overex-
pression, the formation of stress fiber in HCC cells was inhibited, and concurrently, the levels
of active RhoA, Rac1 and Cdc42 were all reduced. As a result of our collective present data, we
therefore propose herein a molecular model, in which miR-101 broadly abrogates HCC tumor-
igenesis and metastasis by a direct suppression of multiple molecular targets and an inactiva-
tion of the RhoA/ROCK pathway (Fig. 5D).
To sum up, herein, we report, for the first time, an essential role for systemic delivery of
lent-miR-101 in the efficient therapy of HCC in a mouse model, and the use of lentivirus
vector has a unique advantage to enhance a transduction and therapeutic abundance of
miRNA in vivo without toxic effects. Furthermore, functional and/or mechanistic studies of
miR-101 as provided in this report, suggest a critical role of miR-101 in the control of HCC
cells cytoskeletal reorganization, EMT, invasiveness and angiogenesis, resulting in a potent
abrogation of HCC development and progression by means of a “one-hit/multiple-targets”
mechanism.
Materials and Methods
Tissue specimens and cell cultures
One hundred and sixty-three cases of blood samples from patients with HCC were obtained
from the residue of patient blood samples for the purpose of clinical diagnosis in the Clinical
Laboratory of Sun Yat-Sen University Cancer Center, Guangzhou, China, between July 2005
and June 2010. The HCC cases selected were based on distinctive pathologic diagnosis, avail-
ability of blood specimens, follow-up data, and had not received previous local or systemic
treatment. In this HCC cohort, 147 cases were HCCs without distant metastasis, 16 HCCs
had distant metastasis. Relevant corresponding clinical data of HCC patients were detailed in
Table 1. In addition, 50 cases of plasma samples from human healthy donors were utilized as
control. Blood samples were processed and plasma was frozen within 2 hours of the blood
draw. In the present study, the informed consents of participants have not been conducted
and given, since 1) the privacy and personal identity information of all participants were pro-
tected, i.e., all the data were analyzed anonymously, 2) all the blood samples were not and
will not be used for any other purpose and 3) the waiver of informed consent did not and will
not have adverse effect on the rights and health of the participants. This study was approved
by the Institute Research Medical Ethics Committee at Sun Yat-Sen University Cancer
Center.
HCC cell lines Hep3B, Bel-7402, SMMC-7721 and MHCC-LM9 were cultured in
RPMI1640 medium with 10% newborn calf serum. Immortalized normal liver cell line MIHA,
human embryonic kidney cell 293FT and HCC Huh-7 and HepG2 lines in DMEM were cul-
tured with 10% fetal bovine serum.
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RNA isolation and quantitative real-time PCR
RNA was isolated from 400ml plasma using the mirVana PARIS kit (Ambion, Carlsbad, CA)
following the manufacturer’s protocol. To allow for normalization of sample to sample varia-
tion in the RNA isolation step, synthetic cel-miR-39 was added to each sample as described by
Mitchell et al [45]. These samples were processed under the exactly same conditions.
To ensure the quality of RNA from plasma, we examined the levels of miR-16, a miRNA
displays the higher stability in plasma [46], in 163 HCC patients and 50 healthy donors. The
results showed that no significant difference was examined in terms of the plasma levels of
miR-16 between healthy donors and HCC patients (S1C Fig.).
Total RNA from cell lines and tissues was extracted with TRIzol reagent (Invitrogen,
Carsbad, CA). cDNA was synthesized with the PrimeScript RT reagent Kit (Promega,
Madison, WI). Real-time PCR was carried out using an ABI 7900HT Fast Real-time PCR sys-
tem (Applied Biosystems, Foster City, CA) according to the manufacturer’s recommended
conditions. The primer sequences are provided in S2 Table.
MicroRNA measurement by real-time PCR was performed in duplicate using Taqman uni-
versal PCR kit and miR-101 and RUN6B/ cel-miR-39 probe (Applied Biosystems, Foster City,
CA), in scaled-down (5mL) reaction volumes using 2.5mL TaqMan 2× Universal PCR Master
Mix with No AmpErase UNG, 0.25mL miRNA-specific primer/probe mix, and 2.25mL diluted
RT product per reaction. At the end of the PCR cycles, melting curve analyses as well as electro-
phoresis of the products on 3.0% agarose gels were performed in order to validate the specific
generation of the expected PCR product. Each sample was run in duplicates for analysis.
4Ct was calculated by subtracting the Ct values of U6/ cel-miR-39 from the Ct values of the
miRNA of interest.44Ct was then calculated by subtracting4Ct of the control from4Ct of
disease. Fold change of gene was calculated by the equation 2−44Ct .
Lentivirus production and HCC cell infection
Virus particles were harvested 48h after pCDH-CMV-miR-101-coGFP or pCDH-CMV-
coGFP (System Biosciences, CA) transfection with the packaging plasmid pRSV/REV,
pCMV/VSVG and pMDLG/pRRE into 293FT cells by using Lipofectamine 2000 reagent
(Invitrogen). Lentivirus-miR-101-coGFP (lent-miR-101) and lentivirus-miR-ctr-coGFP
(lent-miR-ctr) were condensed and purified for 108 MOI/200ml. Next, LM9 and Huh-7 HCC
cells were infected by lent-miR-101 and lent-miR-ctr, respectively, to construct the stable
miR-101-expressing and control HCC cells.
Oligonucleotide transfection
MiR-101 inhibitor was synthesized by Genepharma (Shanghai, China). The sequence of miR-
101 inhibitor is UUCAGUUAUCACAGUACUGUA. SiRNA duplex oligonucleotides targeting
human ROCK2mRNA 5’-CAGAAGCGTTGTCTTATGCAA-3’, targeting human STMN1
mRNA 5’-AAGAGAAACUGACCC-ACAAdTdT-3’ and targeting COX2 mRNA 5’-G
CUGGGAAGCCUUCUCUAAdTdT-3’ were synthesized by Ribobo (Guangzhou, China).
Oligonucleotide transfection was performed with Lipofectamine 2000 reagents (Invitrogen).
Luciferase reporter assay
The putative miR-101 binding sites at the 3’-UTRs of ROCK2, STMN1 and COX2mRNAs
were cloned downstream of the cytomegalovirus (CMV) promoter in a pMIR-REPORT vector
(Ambion). Two mutant constructs were generated by either deletion or mutations. The primers
used are shown in S2 Table.
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The firefly luciferase construct was cotransfected with a control Renilla luciferase vector
into LM9 cells in the presence of either lent-miR-101 or lent-miR-ctr. Dual luciferase assay
(Promega) was performed 48 hours after transfection. The experiments were performed inde-
pendently in triplicate.
Wound healing and invasion assays
Cell migration was assessed by measuring the movement of cells into a scraped, cellular area
created by a 200-ml pipette tube, and the spread of wound closure was observed after 48 hours
and photographed under a microscope. We measured the fraction of cell coverage across the
line for migration rate. For invasion assays, 105 cells were added to a MatrigelTM Invasion
Chamber (BD Biosciences, Becton Dickson Labware, Flanklin Lakes, NJ) present in the insert
of a 24 well culture plate. Fetal bovine serum was added to the lower chamber as a chemoattrac-
tant. After 48 hours, the non-invading cells were gently removed with a cotton swab. Invasive
cells located on the lower side of the chamber were stained with crystal violet, air dried and
photographed. For colorimetric assays, the inserts were treated with 150ml 10% acetic acid and
the absorbance was measured at 560 nm using a spectrophotometer (Spectramax M5).
Western blot analysis and Rho-GTPase activation assay
Proteins were separated on SDS-PAGE and transferred to nitrocellulose membrane (Bio-Rad).
The membrane was blocked with 5% non-fat milk and incubated with the corresponding
mouse anti-ROCK2, EZH2, COX2, E-cadherin, a-catenin, b-catenin, N-cadherin, fibronectin,
vimentin (BD Biosciences, 1:1000 dilution), STMN1 and a-tubulin (Santa Cruz Biotechnology,
Santa Cruz, CA, 1:1000 dilution) and GAPDH (Cell signaling Technology, Beverly, MA, 1:500
dilution) monoclonal antibodies. The proteins were detected with enhanced chemilumines-
cence reagents.
PAK1 PBD-agarose (for isolating Rac1-GTP and cdc42-GTP) and rhotekinagarose (for
isolating Rho-GTP) (Upstate Biotechnology, Lake Placid, NY) were used to pull down the
GTP-bound form of Rho-GTPase according to the manufacturer’s manual. The levels of active
Rac1, cdc42 and RhoA were detected by Western blot using specific polyclonal anti-Rac1
(1:1000), anti-cdc42 (1:1000) and anti-RhoA (1:1000) antibodies (Cell Signaling Technology,
Beverly, MA).
Immunofluorescence (IF)
For the IF studies, cells were fixed with 4% paraformaldehyde in phosphate-buffered saline and
permeabilized with 0.2% Triton X-100 in phosphate-buffered saline. Fixed cells were incubated
with 1:2000 fluorescein isothiocyanate-conjugated phalloidin (Sigma, St. Louis, MO) or anti-
bodies as indicated. Cells were counterstained with 4, 6-diamidino-2-phenylindole (DAPI)
(Calbiochem, San Diego, CA) and imaged with a confocal laser-scanning microscope
(Olympus FV1000, Tokyo, Japan).
Systemic delivery of lent-miR-101 to an orthotopic liver implanted HCC
model of mouse
Male nude mice (BALB/C-nu/nu), 4–5 weeks old, 15–20 g, were obtained from the Center of
Animal Control of Guangdong Province and maintained in an Animal Biosafety Level 3 Labo-
ratory at the Animal Experiment Center of Sun Yat-Sen Cancer Center. We did the experiment
3–5 days after delivery of the mice to allow them to adapt to the environment.
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First, to establish an orthotopic liver implanted HCCmodel of mouse, 2 × 106 populations
of LM9 cells, were injected subcutaneously into the flanks of BALB/C-nu/nu athymic nude
mice. After 2 weeks, the subcutaneous tumors were resected and diced into 1 mm3 cubes,
which were then implanted into the liver of mice. After the model construction, the mice have
been intraperitoneally injected gentamycin in order to prevent abdominal infection, one time
one day for three days. Then lentivirus-miR-101-coGFP (lent-miR-101), lentivirus-miR-ctr-
coGFP (lent-miR-ctr) and physiological saline (NaCl) were administered at a dose of 108 MOI
per animal by tail vein injection (200 ml total volume) using a 30 gauge ultra-fine insulin sy-
ringe at a week after the model construction, 2 times a week for a month. Meanwhile, the gen-
eral health status of the nude mice was observed everyday, including food intake, activity, and
any abnormalities such as diarrhea and dehydration. The body weight was measured every 3
days. When animals became moribund, mice were euthanized by the cervical dislocation meth-
od. The liver and the lungs were removed and fixed with phosphate-buffered formalin. Subse-
quently, consecutive tissue sections were made for each block of the liver and the lung. The
numbers of the intrahepatic and pulmonary metastatic nodules in the liver and the lung were
carefully examined. All experimental procedures involving animals were are accordant with
the Guidelines for the Care and Use of Laboratory Animals (NIH publications Nos. 80–23, re-
vised 1996) and the laboratory animal ethics committee of Sun Yat-Sen University Cancer
Center.
Immunohistochemistry (IHC)
The tissue blocks were cut into 5-mm sections and processed for IHC in accordance with a pre-
viously described protocol. [21]
Experimental in vivo metastasis model
Eight 4-week-old male SCID-Beige mice in each experimental group were injected with lent-
miR-101-LM9, lent-miR-ctr-LM9 and mock-LM9 cells separately. Briefly, 1×105 cells were in-
jected intravenously through tail vein into each SCID mouse in a laminar flow cabinet. Six
weeks after cell injection, mice were sacrificed and examined.
Angiogenesis assay in a chicken chorioallantoic membrane (CAM)
model
Fertilized chicken eggs were purchased from institute of zoo techniques and veterinary science
(Guangzhou, China), and incubated at 37°C with 70% humidity for 8 days. Lent-miR-101,
lent-miR-ctr and mock LM9 cells were re-suspended in PBS buffer solution. Cells (2×106 cells,
15 ml) were mixed with equal volume of Matrigel (BD Biosciences). Aliquots (2×106 cells,
30 ml) of the mixture were then applied onto the CAM of 9-day-old embryos. The area around
the implanted Matrigel was photographed 4 days after the implantation, and the number of
blood vessels was obtained by counting the branching of blood vessels. Assays for each treat-
ment were carried out using 6 chicken embryos.
Statistical analysis
Statistical analysis was performed using a SPSS software package (SPSS Standard version 16.0,
SPSS Inc.). The ROC curve analysis was applied to define a cutoff score for plasma miR-101
level by a 0, 1- criterion[47]. Briefly, the sensitivity and specificity for the outcome (survival
status) were plotted to create a ROC curve. The score localized closest to the point (i.e., 0.0, 1.0)
at the maximum sensitivity and specificity was selected as the cutoff score to determine the
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greatest number of tumors that were correctly classified as having or not having the outcome.
Data derived from cell line experiments are presented as meanSE and assessed by a Two-
tailed Student’s t test. P values of<0.05 were considered significant.
Accession numbers
Human miR-101, MI0000937; human ROCK2, Homo sapiens ROCK2 NM_004850; Human
STMN1, NM_005563.3 Homo sapiens stathmin 1 (STMN1), transcript variant 3, mRNA.
Ethics approval
This study was approved by the Institute Research Medical Ethics Committee of Sun Yat-Sen
University Cancer Center, Guangzhou, China.
Supporting Information
S1 Fig. Analysis of miR-101 levels in human plasma samples by real-time PCR. A. The level
of mature miR-101 in HBV-negative (n = 29) and HBV-positive (n = 134) HCC patient’s plas-
ma. B. The level of mature miR-101 in HBV-negative (n = 5) and HBV-positive (n = 10) HCC
patient’s plasma with distant metastasis. C. CT value of miR-16 in human plasma samples
from healthy donors (normal, n = 50) and HCC patients (n = 163).
(TIF)
S2 Fig. No obviously organ-related toxicity was observed. Lent-miR-101 and control lent-
miR-ctr was administered, respectively, to mice by tail vein at one week after the preparation of
the mouse HCC model, 2 times a week for a month. After the experiment, animals were sacri-
ficed and the organs were fixed in formalin overnight and processed for paraffin embedding.
The paraffin-embedded blocks were sectioned and stained by hematoxylin and eosin.
(TIF)
S3 Fig. STMN1 is the target of miR-101. A. Schematic of predicted miR-101-binding sites in
the 30UTR of STMN1. B.MiR report constructs containing a wild-type and 2 mutated STMN1
3’UTRs were transfected into LM9 cells, respectively. Relative repression of firefly luciferase
expression was standardized to a transfection control. The reporter assays were performed
3 times with essentially identical results. C. Upper, real-time PCR examination of mRNA levels
of ROCK2 between the lenti-miR-101 and control lent-miR-ctr treated LM9 cells. LM9 cells
were infected with lent-miR-ctr or lent-miR-101 for 72 hours. Down, ectopic overexpression of
miR-101 by lenti-miR-101 reduces the levels of STMN1 protein in LM9 cells, as compared to
that in both Mock and lent-miR-ctr treated LM9 cells.D. Protein expression of STMN1 is
up-regulated in HCC HepG2 cells after the down-regulation of miR-101 by anti-miR-101, as
compared to that in control Mock and anti-miR-NC HepG2 cells. E. IHC staining showing
down-regulated expressions of STMN1 in HCC tissues of mice treated with systemic delivery
of lent-miR-101, as compared to that treated with NaCl or lent-miR-ctr.
(TIF)
S4 Fig. Enforced expression of miR-101 in HCC cell line inhibits the mRNA and protein
levels of COX2. A. Enforced overexpression of miR-101 in LM9 cells decreases endogenous
levels of COX2 protein. LM9 cells were infected with Mock, lent-miR-ctr or lenti-miR-101 for
72 hours. COX2 expression was assessed by Western blot. B.MiR report constructs containing
a wild-type and 2 mutated COX2 3’UTRs were transfected into LM9 cells, respectively. Relative
repression of firefly luciferase expression was standardized to a transfection control. The re-
porter assays were performed 3 times with essentially identical results. C. The mRNA levels of
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COX2 in Mock, lent-miR-ctr or lenti-miR-101 LM9 cells examined by Real-time PCR. Lenti-
miR-101 decreased the levels of COX2mRNA in LM9 cells.D.Western blot assay showing
protein levels of COX2 after the treatment of Mock, Anti-miRNC and anti-miR-101 in HepG2
cell line. Anti-miR-101 could increase COX2 expression in HepG2 cells.
(TIF)
S5 Fig. Wound-healing assay demonstrating different cll motilities in lent-miR-ctr, lent-
miR-101, si-STMN1 and si-ROCK2 treated HCC lines LM9 and Huh7. Ectopic overexpression
of miR-101 by infection of lent-miR-101 decreased cell motility in both LM9 and Huh7 cells,
compared with that in lent-miR-ctr control cells. Silence of either ROCK2 or STMN1 by specific
siRNA could partially mimic the inhibiting effect of lent-miR-101 on both HCC cells motilities.
(TIF)
S6 Fig. Ectopic overexpression of miR-101 inhibits HCC Huh7 cell invasion and EMT in
vitro. A. The invasive properties of HCC Huh cells transfected with lent-miR-ctr, lent-miR-
101, si-STMN1, and si-ROCK2 were analyzed by an invasion assay using a Matrigel Invasion
Chamber. Migrated cells were plotted as the average number of cells per field of view from
3 indipendent experiments (, P<0.01). B. Expression levels of the epithelial markers
E-cadherin, a-catenin, b-catenin and the mesenchymal markers fibronectin, N-cadherin and
vimentin were analyzed by Western blot between lent-miR-101 and control lent-miR-ctr treat-
ed Huh cells. C. IF staining was used to compare expression levels/pattern of epithelial markers
and mesenchymal markers (red signal) between the control lent-miR-ctr and lent-miR-101
treated Huh cells. The Epithelial markers E-cadherin, a-catenin, b-catenin were upregulated
and mesenchymal markers fibronectin, N-cadherin and vimentin were downregulated in
lent-miR-101 treated Huh cells, as compare to that in lent-miR-ctr Huh cells.
(TIF)
S7 Fig. Ectopic overexpression of miR-101 inhibits stress fiber formation in vitro. A. Stain-
ing for F-actin demonstrated that the stress fiber formation in lent-miR-101 treated Huh7 cells de-
creased when compared with that in lent-miR-ctr Huh7 cells. B. Total and active forms of Rho-
GTPases, including RhoA, Rac1, and cdc42 were compared between lent-miR-ctr and lent-miR-101
treated Huh7 cells byWestern blot analysis. GTP-bound (active) forms of RhoA, Rac1, and cdc42
were pulled down and examined byWestern blot using corresponding antibodies. Active forms of
RhoA, Rac1 and Cdc42 were lower in lent-miR-101 Huh7 than that in lent-miR-ctr Huh7 cells.
(TIF)
S8 Fig. Enforced expression of miR-101 in HCC cell line inhibits the mRNA and protein
levels of EZH2. A. Enforced overexpression of miR-101 in LM9 cells decreases endogenous
levels of EZH2 protein. LM9 cells were infected with Mock, lent-miR-ctr or lenti-miR-101 for
72 hours. EZH2 expression was assessed by Western blot. B. The mRNA levels of EZH2 in
Mock, lent-miR-ctr or lenti-miR-101 LM9 cells examined by Real-time PCR. Lenti-miR-101
decreased the levels of EZH2mRNA in LM9 cells. C.Western blot assay showing protein levels
of EZH2 after the treatment of Mock, Anti-miRNC and anti-miR-101 in HepG2 cell line. Anti-
miR-101 could increase EZH2 expression in HepG2 cells.
(TIF)
S1 Table.Main serological parameters of 3 groups of nude mice at the study endpoints.
(DOC)
S2 Table. Primers for ROCK2, STMN1 and COX2 3’-UTRs in the luciferase report assay and
real-time PCR primers for ROCK2, STMN1, EZH2 and COX2.
(DOC)
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